ArticleCancer management and research2025
Inhibitory Effects of Paclitaxel-Loaded Iron Oxide Nanoparticles on Non-Small Cell Lung Cancer by Enhancing Autophagy-Dependent Ferroptosis and Apoptosis Pathways.
Article in Cancer management and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Ligand-directed oral lipidic nanoplatform enables sustained ferroptosis and immune reprogramming via multivalent transporter-mediated metronomic delivery.Theranostics · 2026Article
- Crosstalk between autophagy-dependent ferroptosis and PANoptosis in myocardial and cerebral ischemia-reperfusion injury: mechanisms and therapeutic implications.Frontiers in pharmacology · 2026Review
- Smart nanoplatforms for early detection and immune modulation in lung cancer.Frontiers in bioengineering and biotechnology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Iron oxide nanoparticles coated with paclitaxel (IONP@PTX) are frequently applied to various tumor types. However, inhibitory effect and possible mechanism of IONP@ PTX on non-small-cell lung cancer (NSCLC) remain unclear. Objective: This work aimed to assess inhibitory effects and potential mechanisms of IONP@PTX on lung cancer A549 cells and further explore the nanomedicine delivery systems for applications in cancer therapies. Methods: Morphology features and qualities of IONP@PTX were directly assessed. After treatment of A549 cells with either PTX or IONP@PTX, cell viability and apoptosis were separately detected by CCK‑8 assay and flow cytometry. In addition, intracellular iron ion, lipid peroxidation (LPD) and reactive oxygen species (ROS) were identified by using an iron colorimetric assay kit, DCFH-DA and C11-BODIPY fluorescent probe, respectively. Moreover, the expression levels of autophagy-, ferroptosis-, and apoptosis-related proteins were measured by Western blot. Results: The synthesized IONP@PTX had a core particle size of about 10 nm and a hydrated particle size of 31.01±2.47 nm. In comparison with PTX, IONP@PTX had a stronger anti-tumor effect on A549 cells, with considerably higher levels of ROS, LPD, and total iron ion concentration ( Conclusion: IONP@PTX inhibits the proliferation of human lung cancer A549 cells by enhancing autophagy-dependent ferroptosis and apoptosis pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.